Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Insiders fund Gamida Cell’s $10mm Series E financing

Executive Summary

Gamida Cell Ltd. (stem cell therapies) completed a $10mm Series E financing from all major existing backers (possibly including Elbit Imaging, Clal Biotechnology Industries, Israel HealthCare Ventures, Teva Pharmaceutical, Amgen, Denali Ventures, and Auriga Ventures). The money will fund future global marketing of the company’s allogeneic stem cell candidate StemEx, which is in Phase III for leukemia and lymphoma as an alternate to bone marrow transplantation. The US launch is planned for next year. The therapeutic, an expanded population of stem/progenitor cells combined with nonexpanded cells from the same umbilical cord unit, was developed through a joint venture Gamida formed with Teva in 2005. Series E funds will also support a clinical trial evaluating Gamida’s Phase I/II NiCord for sickle cell disease and thalassemia.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies